Last updated: October 31, 2026
Niraparib tosylate, marketed as Zejula by GSK, is an oral PARP inhibitor used primarily as maintenance therapy for advanced ovarian, fallopian-tube, and primary peritoneal cancers. Its commercial trajectory has been shaped by rapid PARP-class competition, narrower late-line treatment opportunities, safety-related prescribing constraints, and GSK’s decision to prioritize first-line maintenance rather than expand treatment indications.
GSK acquired Zejula through its approximately $5.1 billion acquisition of Tesaro in 2019. The drug remains commercially relevant, but its long-term value depends on first-line maintenance durability, biomarker-defined use, pricing, and the timing of generic niraparib entry. Niraparib is a small molecule, so biosimilar competition is not applicable. Future competition will come through abbreviated new drug applications, patent challenges, and rival PARP inhibitors.
What is niraparib tosylate and how does Zejula work?
Niraparib tosylate is the tosylate salt of niraparib, an orally administered inhibitor of poly(ADP-ribose) polymerase 1 and 2, or PARP1/2. PARP inhibition impairs DNA single-strand break repair and can produce synthetic lethality in tumors with defective homologous recombination repair, including some BRCA1- or BRCA2-mutated cancers.
Zejula is supplied as capsules and tablets. The tablet formulation reduced the drug’s starting dose for some patients and was intended to improve exposure management and tolerability compared with the original capsule regimen.
FDA regulatory status
The FDA approved Zejula in March 2017 for maintenance treatment of adults with recurrent epithelial ovarian, fallopian-tube, or primary peritoneal cancer responding to platinum-based chemotherapy. The approval was initially granted without restricting use by BRCA status.
The FDA expanded Zejula into first-line maintenance treatment for advanced ovarian, fallopian-tube, and primary peritoneal cancers in April 2020. The approval was supported principally by the PRIMA trial, which showed a larger progression-free-survival benefit in homologous-recombination-deficient disease than in the overall population. The FDA label includes dose individualization based on baseline body weight and platelet count. (U.S. Food and Drug Administration [FDA], 2023)
In 2022, GSK withdrew the U.S. accelerated-approval indication for treatment of patients with advanced ovarian, fallopian-tube, or primary peritoneal cancer who had received at least three prior chemotherapy regimens and whose tumors were associated with homologous recombination deficiency. The withdrawal reflected confirmatory-study results and the changing regulatory standard for late-line PARP use.
What patents protect niraparib tosylate?
Niraparib is protected by a composition-of-matter patent family and later patents covering solid forms, pharmaceutical compositions, and dosage formulations. The principal U.S. patent estate has historically included the following records:
| Patent |
General subject matter |
Approximate U.S. term position |
Commercial relevance |
| US 8,071,613 |
Niraparib chemical compounds and related pharmaceutical use |
2026-2027 range before any applicable adjustments |
Core composition-of-matter protection |
| US 9,758,527 |
Niraparib formulations and pharmaceutical compositions |
Early-to-mid 2030s range |
Potential barrier to capsule or tablet products |
| US 10,183,020 |
Additional formulation or dosage protection |
Mid-2030s range |
May affect specific generic presentations |
| Subsequent continuation patents |
Formulation, dosing, and method-of-use claims |
Varies by patent and terminal-disclaimer status |
Can extend practical litigation exposure |
The Orange Book, rather than a commercial patent database, controls the FDA-listed patent record relevant to an ANDA certification. Patent numbers, expiration dates, pediatric extensions, terminal disclaimers, and listing status can change as the FDA updates the Orange Book. (FDA, 2024a; U.S. Patent and Trademark Office [USPTO], 2024)
What formulations are protected by niraparib patents?
The formulation estate is commercially important because generic applicants must develop an equivalent oral product while addressing any listed patents covering:
- Niraparib tosylate solid forms
- Immediate-release capsules
- Film-coated tablets
- Pharmaceutical compositions with defined excipient systems
- Dose-adjusted tablet regimens
- Methods for reducing hematologic toxicity through individualized dosing
The most defensible formulation claims are those tied to a specific solid state, dissolution profile, particle-size distribution, or composition. Broad treatment claims are generally more exposed to invalidity and obviousness challenges than narrowly defined pharmaceutical-formulation claims.
How strong is the niraparib patent estate?
The estate is moderately strong through the late 2020s because the core compound patent can delay generic entry. Protection becomes more fragmented after that point. Later formulation patents may support additional litigation but are less likely to block every generic niraparib product if an applicant can design around the claimed tablet, capsule, excipient, or dosing features.
The commercial value of late-expiring patents depends on whether they cover the marketed product as a whole or only a particular presentation. A formulation patent that does not cover all medically necessary dosing options may support litigation leverage without guaranteeing a complete market exclusion.
When does niraparib lose exclusivity?
Niraparib’s main U.S. exclusivity risk is expected to arise in stages rather than on one date.
| Exclusivity layer |
Expected timing |
Impact |
| Core compound protection |
Approximately 2026-2027 |
Primary barrier to conventional generic entry |
| Formulation and dosage patents |
Approximately 2030-2035, depending on patent |
May delay particular generic products |
| FDA regulatory exclusivity |
Largely expired |
No meaningful remaining new-drug exclusivity from the 2017 approval |
| Pediatric exclusivity |
Must be confirmed against current FDA records |
Could add six months if granted for an eligible patent |
| Generic entry |
Potentially before nominal patent expiry through settlement or successful Paragraph IV litigation |
Depends on litigation outcome and settlement terms |
A generic applicant may file an ANDA with a Paragraph IV certification before the core patents expire. That filing can trigger patent litigation and, if the reference-listed drug holder sues within the statutory period, a 30-month stay of ANDA approval subject to court and regulatory events. (FDA, 2024b)
Has niraparib faced Paragraph IV challenges?
Public generic filings and patent litigation are the key indicators of near-term entry risk. Niraparib is exposed to Paragraph IV challenges because its core product patent approaches the end of its ordinary term and because the product has sufficient commercial value to justify generic development.
The practical risk is higher for a generic capsule or tablet that directly matches Zejula’s marketed dosage form. A challenger may certify Paragraph IV against selected patents while conceding that other patents are not infringed, invalid, or unenforceable. The resulting litigation may produce:
- A court judgment allowing entry before patent expiration.
- A settlement with an agreed launch date.
- A judgment sustaining one or more blocking patents.
- A product launch after the core patent expires but before later formulation patents expire.
No biosimilar pathway applies. Niraparib is a chemically synthesized small molecule regulated through the ANDA pathway, not the biologics license application and biosimilar pathway.
What is the Orange Book status of Zejula?
Zejula is listed in the FDA Orange Book as a prescription drug marketed by GSK under a new drug application. The Orange Book identifies patents that GSK or its predecessor has submitted as covering the drug substance, drug product, or approved method of use.
The central Orange Book questions for a generic applicant are:
- Which patents remain listed?
- Do listed patents cover the active ingredient or only a formulation?
- Are any patents subject to terminal disclaimers?
- Does the proposed ANDA product use a different formulation or dosage approach?
- Has the applicant made Paragraph IV certifications?
- Has a 30-month stay been triggered?
Orange Book listing alone does not prove that a patent is valid, infringed, or enforceable. Those issues are determined through litigation or settlement.
What patent litigation affects niraparib?
Niraparib litigation risk is concentrated in Hatch-Waxman cases involving ANDA applicants. These disputes typically focus on claim construction, obviousness, written description, enablement, salt and polymorph characterization, and whether the proposed generic product practices formulation claims.
Core compound claims usually generate the highest-value dispute because they cover the active pharmaceutical ingredient. Formulation cases have narrower economic scope but can still delay a product that relies on the same dose form or release profile.
A settlement that permits an authorized generic or a delayed generic launch can materially change the commercial forecast. The absence of a publicly confirmed settlement does not eliminate entry risk because an ANDA applicant can continue through litigation and seek a judgment before the listed patent term ends.
How does Zejula compare with competing PARP inhibitors?
| Drug |
Company |
Main commercial position |
Competitive pressure |
| Zejula, niraparib |
GSK |
Broad first-line and recurrent maintenance positioning |
Hematologic toxicity, dose reductions, and PARP-class competition |
| Lynparza, olaparib |
AstraZeneca/Merck |
Strong BRCA-focused franchise and broader combination development |
Large clinical dataset and established physician adoption |
| Rubraca, rucaparib |
Clovis, later acquired through bankruptcy assets |
Recurrent ovarian cancer and maintenance history |
Weaker financial position and narrower commercial scale |
| Talzenna, talazoparib |
Pfizer |
Breast and prostate cancer indications |
Less direct ovarian-cancer overlap but competes for PARP prescribing and oncology budgets |
Olaparib has the strongest global commercial position in the PARP class. Niraparib’s competitive advantage is its once-daily oral dosing and first-line maintenance positioning across biomarker groups. Its disadvantages include thrombocytopenia, anemia, nausea, fatigue, hypertension, and the need for individualized dosing.
What is the financial trajectory for Zejula?
GSK’s acquisition of Tesaro placed a multibillion-dollar valuation on Zejula and Tesaro’s pipeline. The transaction reflected expectations that Zejula could become a major oncology product with broad ovarian-cancer maintenance use. The subsequent market has been more constrained.
Revenue drivers
Zejula revenue depends on:
- Number of eligible first-line maintenance patients
- Duration of maintenance treatment
- Use in homologous-recombination-deficient and BRCA-mutated tumors
- Share relative to Lynparza and Rubraca
- Treatment discontinuation caused by adverse events
- Net price after rebates and payer discounts
- Generic entry timing
Revenue pressures
The principal pressures are clinical and commercial:
- PARP class labels have narrowed in some late-line settings.
- Confirmatory trials weakened the case for broad heavily pretreated use.
- Physicians increasingly select patients using BRCA and homologous-recombination biomarkers.
- Competing PARP inhibitors have stronger brand recognition or larger combination programs.
- Hematologic toxicity can reduce persistence and increase monitoring costs.
- The product has limited expansion potential outside ovarian, fallopian-tube, and primary peritoneal cancers.
GSK has not publicly identified Zejula as a principal growth engine on the scale of its respiratory, HIV, vaccine, or specialty-medicine franchises. The acquisition therefore carries a declining-return profile unless first-line maintenance volumes remain durable or new tumor types expand the addressable market. GSK’s annual reports provide the controlling figures for reported sales, regional performance, and growth rates. (GSK plc, 2023, 2024)
What generic entry scenarios exist for niraparib?
Scenario 1: Entry after core compound expiry
This is the most straightforward pathway. Generic manufacturers enter once the core patent expires and any applicable litigation stay ends. Price erosion would likely be rapid because oral oncology products with multiple ANDA filers often experience substantial discounting.
Scenario 2: Early entry through settlement
GSK could agree to a licensed entry date before the last asserted patent expires. The settlement may include restrictions on launch timing, authorized-generic rights, or limitations on the generic product’s dosage form.
Scenario 3: Court victory for a generic applicant
A finding that a listed patent is invalid, not infringed, or unenforceable could allow entry before nominal expiration. The highest-risk claims would likely involve obviousness and the scope of formulation patents.
Scenario 4: Delayed entry caused by formulation patents
A generic could enter with a legally distinct formulation while a competing product remains blocked by narrower formulation claims. This would reduce GSK’s exclusivity without eliminating all patent-related barriers.
Which companies could challenge Zejula?
Potential challengers include large generic manufacturers with oncology capabilities, such as Teva, Sandoz, Viatris, Dr. Reddy’s Laboratories, Sun Pharma, Cipla, and Hikma. The actual competitive set depends on ANDA filings, Paragraph IV certifications, manufacturing capacity, and the economics of launching a generic oncology product.
Geographic competition will emerge at different times. U.S. entry is governed by Hatch-Waxman patents and FDA approval. European entry depends on national validation, supplementary protection certificates, unitary-patent exposure, and local litigation. Markets such as India and other emerging jurisdictions may experience earlier competition if local patent coverage is weaker or if enforcement differs from the United States.
What manufacturing and intellectual-property barriers remain?
Niraparib manufacturing is less technically difficult than biologic production, but commercial-scale supply still requires control of:
- Active pharmaceutical ingredient purity
- Salt formation and crystallinity
- Polymorph consistency
- Residual solvents and impurities
- Tablet or capsule content uniformity
- Stability under long-term storage
- Bioequivalence across the proposed generic formulation
The most important IP barrier is the combination of composition-of-matter protection and formulation patents. Manufacturing know-how may increase cost and delay but generally does not create the same durable exclusion as an enforceable patent.
Key Takeaways
- Niraparib tosylate is marketed by GSK as Zejula and is primarily a maintenance PARP inhibitor for ovarian-cancer-related indications.
- GSK acquired Tesaro for approximately $5.1 billion, making Zejula a major component of the transaction thesis.
- The core U.S. compound patent is expected to lose ordinary-term protection around 2026-2027, subject to current Orange Book records and any applicable adjustments.
- Later formulation and dosage patents may extend litigation risk into the early or mid-2030s without necessarily blocking every generic presentation.
- FDA regulatory exclusivity has largely expired, and future competition will come through ANDAs rather than biosimilars.
- The commercial trajectory is pressured by PARP-class competition, safety-related dose reductions, narrower late-line use, and limited tumor-type expansion.
- First-line maintenance is the main defense against revenue erosion.
- Generic entry could occur after core patent expiry, through settlement, or earlier if a challenger defeats asserted patents.
FAQs About Niraparib Tosylate Exclusivity and Market Risk
Is niraparib tosylate the same as niraparib?
Yes. Niraparib tosylate is the marketed salt form of niraparib used in Zejula tablets and capsules.
Does niraparib have a biosimilar competitor?
No. Niraparib is a small-molecule drug. Competitors will seek FDA approval through the ANDA generic-drug pathway.
Which PARP inhibitor is the strongest competitor to Zejula?
Olaparib, marketed as Lynparza, is the strongest direct commercial competitor because of its broad clinical evidence, BRCA positioning, combination development, and established oncology adoption.
Can a generic launch before the niraparib compound patent expires?
Yes. A generic applicant can seek early entry through a successful Paragraph IV challenge or a settlement with the patent holder. Otherwise, the applicant generally must wait for patent and regulatory barriers to clear.
Does the Zejula tablet patent block all generic niraparib products?
Not necessarily. A tablet patent may block products that practice its specific claims while leaving room for a legally distinct formulation, subject to bioequivalence, patent scope, and litigation outcomes.
References
-
AstraZeneca. (2024). Annual report and Form 20-F 2023. https://www.astrazeneca.com/investor-relations/annual-reports.html
-
GlaxoSmithKline plc. (2023). Annual report 2022. https://www.gsk.com/en-gb/investors/annual-reports/
-
GlaxoSmithKline plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-reports/
-
U.S. Food and Drug Administration. (2023). Zejula prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024b). Hatch-Waxman exclusivity and patent certification resources. https://www.fda.gov/drugs/development-resources
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Public Search. https://www.uspto.gov/patents/search/advanced-search/patent-public-search
